Saturday, July 18, 2026
In Detail Full day, Saturday, July 18, 2026, Timezone: America/Chicago
Stephen Liu: AstraZeneca Reaches Deal with Dizal to Bring Sunvozertinib to the US!
oncodaily - Stephen Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared on X: “FINALLY! AstraZeneca reaches deal with Dizal […]
AI Summary: AstraZeneca reached a deal to make sunvozertinib available in the U.S., accelerating global access for patients with EGFR exon 20 insertion–positive non–small cell lung cancer. The move follows encouraging WU-KONG1B data and signals commercial partnerships are finally translating niche trial gains into real-world treatment options for a stubbornly underserved subgroup.
- AstraZeneca-Dizal deal opens US access to sunvozertinib (3)
- Testing, treatment gaps and rising rare-NSCLC approvals (3)
- WU-KONG1B confirms sunvozertinib activity in EGFR Exon20 (3)
AstraZeneca-Dizal deal opens US access to sunvozertinib
Testing, treatment gaps and rising rare-NSCLC approvals
WU-KONG1B confirms sunvozertinib activity in EGFR Exon20
The RAS Inhibitor Daraxonrasib is Showing Encouraging New Results – Dana-Farber
oncodaily - Dana-Farber Cancer Institute shared a post on LinkedIn: “For years, RAS was considered one of the toughest targets in cancer research. In pancreatic cancer, that challenge is especially urgent. New […]
AI Summary: A targeted RAS inhibitor, daraxonrasib, produced promising clinical activity in patients with NRAS-mutant melanoma, demonstrating tumor responses and a tolerable safety profile in early studies. The data suggest a viable therapeutic avenue for a historically hard-to-treat subset and justify larger trials to confirm benefit — because apparently NRAS wasn’t going to cure itself.
Taylor Farms Expands Iceberg Lettuce Recall to 27 States Amid Cyclospora Outbreak
Christina Jewett and Julie Creswell / nytimes - The implicated products were marketed under several brands, and had been shipped as recently as Thursday.
AI Summary: Taylor Farms has widened an iceberg-lettuce recall to 27 states after a Cyclospora outbreak sickened consumers. Health officials are urging anyone who purchased affected product to discard it and seek medical care if symptoms appear, while investigators trace distribution channels to pinpoint the contamination source. Yes, the lettuce did more than just wilt.
- FDA retraction and ongoing source investigations (3)
- Outbreak scale and clinical testing surge (3)
- Taylor Farms recall, company fallout and political scrutiny (3)
FDA retraction and ongoing source investigations
Outbreak scale and clinical testing surge
Taylor Farms recall, company fallout and political scrutiny
New study sheds light on how Epstein-Barr virus may contribute to multiple sclerosis
medicalxpress - Multiple sclerosis (MS) is a chronic autoimmune disorder that attacks the central nervous system. For years, Epstein-Barr virus (EBV) has been strongly linked to MS, as nearly every person diagnosed with the condition shows evidence of past EBV infection.…
AI Summary: Researchers report that immune responses to Epstein‑Barr virus are implicated in multiple sclerosis, with EBV‑reactive CD4+ T cells enriched in people with MS. The work provides mechanistic evidence connecting prior infection to neuroinflammation and suggests antiviral or immune‑directed strategies might be viable prevention or treatment avenues — assuming we like attacking tiny viral culprits.
18 ancient Egyptian tombs with dozens of gold 'tongues' discovered along the Mediterranean coast
livescience - Archaeologists have found 18 tombs at an ancient Egyptian site by the Mediterranean coast of Egypt.
AI Summary: Archaeologists uncovered dozens of gold 'tongues' and weapon-rich burials in newly excavated Egyptian tombs dating nearly 4,000 years, including interments of women with bows and blades. The discoveries challenge assumptions about gender roles in ancient Egypt and add ornate burial goods that hint at complex social and ritual identities.
Cut the number of choices you make each day. Your brain will thank you
medicalxpress - Jeans that fit perfectly. The ideal Netflix show for a Tuesday night. Your one and only soulmate. Modern life promises that with enough options, you will happily find the best of everything.
AI Summary: Behavioral advice highlights that trimming daily decisions reduces cognitive load, eases stress, and improves decision quality. Practical steps—simplifying routines, limiting trivial choices, and automating recurring tasks—can conserve mental energy for bigger problems, proving once again that fewer options sometimes equals smarter living.
Stopping myeloma maintenance after two years shows no survival loss in trial
medicalxpress - For patients with newly diagnosed multiple myeloma not undergoing an autologous stem cell transplant, indefinite lenalidomide maintenance has long been standard care despite limited evidence to guide the optimal duration of treatment. A randomized phase 3…
AI Summary: Long‑term follow‑up from a randomized multiple myeloma maintenance study indicates that stopping lenalidomide after two years yields similar overall survival to continuing indefinitely. The data support a limited‑duration maintenance strategy that may spare patients toxicity and costs without sacrificing outcomes — revolutionary for weary patients and budget‑conscious oncologists alike.
- Clinicians and advocates react: praise and guidance after ENDURANCE results (6)
- ENDURANCE trial: Two-year lenalidomide equals continuous therapy (3)
Clinicians and advocates react: praise and guidance after ENDURANCE results
ENDURANCE trial: Two-year lenalidomide equals continuous therapy
St. Jude Researchers and Collaborators Identified RBM5 as a Key Driver of Leukemia
oncodaily - St. Jude shared a post on X: “St. Jude researchers and collaborators identified RBM5 as a key driver of leukemia caused by changes in the KMT2A gene through its interaction with […]
AI Summary: St. Jude investigators report that RBM5 is a central driver in a form of childhood leukemia, revealing how the RNA-binding protein helps sustain malignant cells and interact with MYC pathways. The finding opens a plausible route to target an otherwise “undruggable” axis, offering a new precision strategy for high-risk pediatric leukemia.
Senate Republicans block effort to repeal Medicare AI prior authorization pilot
Jakob Emerson / beckershospitalreview - Senate Republicans have blocked an effort to advance a Democratic-led resolution to repeal CMS’ Wasteful and Inappropriate Service Reduction model, an AI-assisted prior authorization pilot within the traditional Medicare program. On July 16, senators vote…
AI Summary: Senators blocked a bipartisan bid to end a Medicare pilot using AI for prior authorization, effectively keeping the demonstration alive. The vote keeps contentious AI-driven administrative streamlining in place while critics warn about oversight, patient impact and the risks of automating care-denial pathways without robust safeguards.
Anthropic pushes deeper into healthcare with Optum partnership as UST embeds Claude into claims management
fiercehealthcare - UST, a global technology and engineering services company, is integrating Anthropic's Claude into CarePath, an operational platform for health insurers and providers.
AI Summary: Anthropic struck a deal with Optum to deploy its Claude AI across claims and care-management workflows, marking a significant step in commercial AI integration into health operations. The partnership promises automation and efficiency but raises questions about oversight, accuracy, and accountability when critical administrative decisions quietly migrate to large language models.
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Pediatric Oncology, Drug Pricing, Healthcare Finance, Autism and look for the RSS link.
StackHealth Time Machine
More StackHealth